Treatment centers across the United States are failing to offer adolescent patients—those 16 years of age and older—with opioid use disorder (OUD) buprenorphine, which is the only FDA-approved OUD medication for this group.
The Society for Adolescent Health and Medicine also recommends buprenorphine, in conjunction with behavioral therapy, as treatment for OUD in this population.